Sugi Predict

Sugi Predict / Compounds / SCHEMBL2706260

SCHEMBL2706260

SCHEMBL2706260

CC(C)c1ccc2c(c1)sc1c3ccc(C(C)C)cc3sc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ SCN4A P35499 1/20 0.46
▸ PARP15 Q460N3 1/20 0.40
▸ PARP10 Q53GL7 1/20 0.40
▸ TNKS2 Q9H2K2 1/20 0.40
▸ PARP2 Q9UGN5 1/20 0.40
▸ KIF11 P52732 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ TRPA1 O75762 1/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ CACNA1C Q13936 1/20 0.38
▸ PIM1 P11309 1/20 0.37
▸ PIM2 Q9P1W9 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ ALOX12 P18054 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2756756 0.91 RAB9A (0.40) RAB9ANPC1SMN1; SMN2SCN4APARP15
SCHEMBL22000096 0.91 KIF11 (0.46) RAB9ANPC1SMN1; SMN2SCN4APARP15
SCHEMBL14327686 0.88 ALDH1A1 (0.40) RAB9ANPC1SMN1; SMN2SCN4APARP15
SCHEMBL13084833 0.86 RAB9A (0.48) RAB9ANPC1SMN1; SMN2SCN4APARP15
SCHEMBL18462668 0.86 NPC1 (0.37) RAB9ANPC1SMN1; SMN2SCN4APARP15
SCHEMBL24245990 0.85 LIMK1 (0.46) RAB9ANPC1SMN1; SMN2SCN4AKIF11
SCHEMBL13506646 0.81 KIF11 (0.45) RAB9ANPC1SMN1; SMN2SCN4APARP15
SCHEMBL19598896 0.81 NPC1 (0.39) RAB9ANPC1SMN1; SMN2SCN4APARP15
SCHEMBL24667827 0.79 KIF11 (0.39) RAB9ANPC1SMN1; SMN2SCN4APARP15
SCHEMBL27252055 0.79 KIF11 (0.42) RAB9ANPC1SMN1; SMN2SCN4APARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11316118-B2 Dibenzo[d,B]silole-based reactive mesogens LOMOX LIMITED (GB) 2022-04-26 — — US disclosed
EP-3523313-B1 DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS LOMOX LTD (GB) 2021-05-05 — — EP disclosed
US-20190280223-A1 DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS LOMOX LIMITED (GB) 2019-09-12 — — US disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 — — US disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 — — US disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 — — EP disclosed
WO-2018065786-A1 DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS LOMOX LIMITED (GB) 2018-04-12 — — WO disclosed
US-20170029408-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-02-02 — — US disclosed
US-20170029408-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-02-02 — — US disclosed
US-9511056-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2016-12-06 — — US disclosed
US-20140051656-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-20 — — US disclosed
US-20140039021-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-06 — — US disclosed
US-8575118-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-11-05 — — US disclosed
US-20130137877-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-05-30 — — US disclosed
US-20120264711-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-10-18 — — US disclosed
US-20120264711-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-10-18 — — US disclosed
US-8273341-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-09-25 — — US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 — — US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 — — US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051656-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 RAB9A 1694/4885NPC1 516/4885SMN1; SMN2 1564/4885
US-20190280223-A1 DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS CCNB1, CCNE2, UBE2G2 RAB9A 3582/4885NPC1 4651/4885SMN1; SMN2 2854/4885
US-11316118-B2 Dibenzo[d,B]silole-based reactive mesogens CCNB1, CCNE2, UBE2G2 RAB9A 3582/4885NPC1 4651/4885SMN1; SMN2 2854/4885
US-20170029408-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 RAB9A 1694/4885NPC1 516/4885SMN1; SMN2 1564/4885
US-20130137877-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 RAB9A 1694/4885NPC1 516/4885SMN1; SMN2 1564/4885
US-20120264711-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 RAB9A 1694/4885NPC1 516/4885SMN1; SMN2 1564/4885
US-20120157404-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 RAB9A 1694/4885NPC1 516/4885SMN1; SMN2 1564/4885
US-20140039021-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 RAB9A 1694/4885NPC1 516/4885SMN1; SMN2 1564/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 RAB9A 1694/4885NPC1 516/4885SMN1; SMN2 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.